Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review

ConclusionThe combination of durvalumab plus tremelimumab showed some oncological advantages in comparison with traditional chemotherapies in some subsets of tumors, but generally has not shown consistent advantages in comparison with the employment of durvalumab monotherapy. A number of the studies examined had intrinsic methodological limitations; therefore, future well-designed studies involving larger cohorts are warranted.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research